Clinical trials: Anti-obesity Agents
Drug Toxicity
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects
To Evaluate the safety and tolerability after KD101 single oral dosing in healthy male subjects To Evaluate the pharmacokinetic property after KD101 single oral dosing in healthy male subjects To Evaluate the effect of food on…
- Trial name
- NCT01979380
- Testing
- KD101
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Lymphocytes, Weight Loss
Effect of Weight Reduction on Immunity
This study included two groups of premenopausal healthy obese women. Experimental group underwent a weight loss program involved a low calorie diet plus anti-obesity drugs and moderate physical activity and control group…
- Conditions
- Lymphocytes, Weight Loss, Viral Diseases, Immunity
- Trial name
- NCT03336086
- Testing
- weight loss program
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Shiraz University of Medical Sciences
Healthy
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
This is a Phase 1, open-label, randomized, single-dose, 2-way crossover study in healthy adult subjects to assess the bioequivalence of naltrexone SR/bupropion SR combination trilayer tablets prepared at two different…
- Trial name
- NCT02259179
- Testing
- Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety
This primary purpose of this study is to determine if ATHX-105 phosphate causes weight loss over a 12-week period.
- Trial name
- NCT00735683
- Testing
- ATHX-105 phosphate
- Sponsor
- Healios K.K.
Obesity (Disorder), Anti-obesity Agents
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1…
- Conditions
- Obesity (Disorder), Anti-obesity Agents, Precision Medicine
- Trial name
- Diagenix (NCT07653412)
- Testing
- Semaglutide or Tirzepatide
- Where
- Greece
- Volunteers
- 220 people
- Sponsor
- National and Kapodistrian University of Athens
Obesity, Overweight
Teaching Obesity Treatment Options to Adult Learners (TOTAL): A Multisite RCT
Nearly 8 in 10 Veterans meet criteria for overweight/obesity. Three evidence-based treatment options are available within VA (behavioral weight management [MOVE!], obesity medications, and bariatric surgery).
- Trial name
- TOTAL (NCT05346575)
- Testing
- Teaching Obesity Treatments to Adult Learners (TOTAL), Usual care
- Where
- 2 sites in United States
- Volunteers
- 440 people
- Sponsor
- VA Office of Research and Development
Idiopathic Intracranial Hypertension, Intracranial Pressure
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
50 patients with verified new-onset Idiopathic Intracranial Hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with Semaglutide…
- Conditions
- Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity, Pseudotumor Cerebri Syndrome
- Trial name
- IIH:DUAL (NCT06027567)
- Testing
- Semaglutide, Very Low Calorie Diet, Dietician counselling
- Where
- 2 sites in Denmark
- Volunteers
- 38 people
- Sponsor
- Rigmor Højland Jensen
Diabetes Mellitus, Obesity
A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
This study compares two types of diet interventions: a low carbohydrate ketogenic diet (Atkins) and a low-fat diet combined with a medication (Orlistat).
- Trial name
- NCT00108524
- Testing
- Low carbohydrate ketogenic diet, Orlistat, Low-fat diet
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Endometrial Cancer, Atypical Hyperplasia
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer.
- Conditions
- Endometrial Cancer, Atypical Hyperplasia, Fertility Perservation
- Trial name
- WE-FiERCE (NCT06073184)
- Testing
- Wegovy, Mirena
- Where
- Canada
- Volunteers
- 71 people
- Sponsor
- GynOncTrials
Obesity, Appetite Regulation
Tailoring Obesity Treatment Trial
The two main aims of this clinical study is; 1. To investigate if the results from a series of physiological tests and questionnaires prior to treatment, can be used to predict the treatment response to obesity medication 2.
- Conditions
- Obesity, Appetite Regulation, PreDiabetes
- Trial name
- TOTT (NCT06619015)
- Testing
- Pramlintide Acetate 1 MG/ML, Semaglutide Pen Injector, Sodium Chloride 0.9% Inj
- Where
- Denmark
- Volunteers
- healthy volunteers welcome
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Obesity
Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss.
- Trial name
- NCT03779048
- Testing
- Behavioral Treatment, Phentermine 15 MG
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University of Pennsylvania
Dengue, Viral Infection
Metformin in Dengue With Obesity
This study aims to investigate the effect of metformin as host-directed therapy in obese/overweight patients with dengue Primary Objective To evaluate the safety and tolerability of metformin in obese/overweight young adults and…
- Conditions
- Dengue, Viral Infection, Metformin, Anti-inflammatory Agents
- Trial name
- MeDO (NCT04377451)
- Testing
- Metformin
- Where
- Vietnam
- Volunteers
- 120 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Hypertension, Obesity & Overweight
A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
Hypertension is the leading risk factor for death globally, affecting approximately 30% of adults in the United Kingdom. Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men…
- Trial name
- SOLUTION-Pilot (NCT07364175)
- Testing
- Tirzepatide, Anti-Hypertensive medications
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
C-reactive Protein, Inflammation
Obesity, Inflammation and Oxidative Stress
The purpose of this study is to determine whether or not Vitamin C (1000 mg/day) can reduce markers of inflammation, especially C-reactive protein (CRP), in obese persons with baseline CRP greater than 1 mg/dl.
- Conditions
- C-reactive Protein, Inflammation, Obesity, Oxidative Stress
- Trial name
- NCT01028976
- Testing
- Vitamin C (ascorbic acid)
- Where
- United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Obesity, Overweight
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
- Trial name
- NCT00532779
- Testing
- Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Ancillary therapy
- Where
- 34 sites in United States
- Volunteers
- 1,742 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity, Insulin Resistance
The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity
BACKGROUND: The relation between gut microbiota and obesity originates from animal studies, showing that the change of gut microbiota can induce changes in both insulin resistance and body composition.
- Trial name
- ANTIBIOTICS (NCT02241421)
- Testing
- Amoxicillin, Vancomycin
- Where
- Netherlands
- Volunteers
- 57 people
- Sponsor
- Maastricht University Medical Center
Inflammation, Obesity and Type 2 Diabetes
Inflammation's Impact on Heart Disease and Diabetes
The goal of this observational study is to evaluate the inflammatory response associated with cardiometabolic diseases, and whether these can be reduced by ex vivo treatment with therapeutic agents.
- Conditions
- Inflammation, Obesity and Type 2 Diabetes, Obesity, Metabolic Syndrome
- Trial name
- INFO (NCT06752018)
- Testing
- Gastric bypass
- Where
- Denmark
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Drug Discontinuation, Substance Use Disorders
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages…
- Conditions
- Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
- Trial name
- CLIN-GLP1 (NCT07387796)
- Testing
- Discontinuation and Reinitiation of Tirzepatide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas at Dallas
Obesity
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.
- Trial name
- NCT00650806
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company